Inflammation as cause for scar cancers of the lung

Integrative Cancer Therapies

Volumn 2, Issue 3, 2003, Pages 238-246

  Ardies, C Murray ^a,b  

^a NORTHEASTERN ILLINOIS UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Cancer; Infection; Inflammation; Prevention; Risk

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; GROWTH FACTOR; LEUKOTRIENE; PROSTAGLANDIN; PROTEIN BCL 2; PROTEIN P21; REACTIVE OXYGEN METABOLITE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RISK; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CELL MUTANT; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DIET; DISEASE ASSOCIATION; DNA DAMAGE; ENZYME ACTIVITY; FIBROSIS; HORMONE SYNTHESIS; HUMAN; INFLAMMATION; INHIBITION KINETICS; LIFESTYLE; LUNG CARCINOGENESIS; LUNG CARCINOMA; LUNG PARENCHYMA; LYMPH; MACROPHAGE ACTIVATION; MUTAGENESIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGENY; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RECURRENT INFECTION; SCAR; SIGNAL TRANSDUCTION; TUBERCULOSIS; WOUND HEALING;

APOPTOSIS; CICATRIX; DIET; DNA DAMAGE; HUMANS; INFLAMMATION; LIFE STYLE; LUNG NEOPLASMS; MYCOBACTERIUM TUBERCULOSIS; REACTIVE OXYGEN SPECIES; RECURRENCE; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 0141539521     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735403256332     Document Type: Article

References (87)

1. Pass HI, Mitchell JB, Johnson DH, Turisi AT, Minna JD, eds. Lung Cancer. Principles and Practice. Philadelphia: Lippencott, Williams, and Wilkins; 2002:461.
2. Shimosato YO, Suzuki A, Hashimoto T, et al. Prognostic implications of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol. 1980;4:365-373.
3. Cagle PT, Cohle SD, Greenberg SD. Natural history of pulmonary scar cancers. Clinical and pathologic implications. Cancer. 1985;56:2031-2035.
4. Kung IT, Lui IO, Loke SL, et al. Pulmonary scar cancer. A pathologic reappraisal. Am J Surg Pathol. 1985;9:391-400.
5. el-Torkey M, Giltman LI, Dabbous M. Collagens in scar carcinoma of the lung. Am J Pathol. 1985;121:322-326.
6. Kazerooni EA, Bhalla M, Shepard JA, McLoud TC. Adenosquamous carcinoma of the lung: radiologic appearance. Am J Roentgenol. 1994;163:301-306.
7. Terzakis JA. X-ray microanalysis of peripheral lung carcinomas. Ultrastruct Pathol. 1995;19:167-173.
8. Shuke N, Tonami N, Shintani H, et al. Differential uptake of TI-201 by small-cell lung cancer in a patient with pneumoconiosis-related pulmonary nodules. Clin Nucl Med. 1999;24:687-690.
9. Kita Y, Kondo D, Nogimura H, Suzuki K, Kazui T. Resected early lung cancer with pulmonary aspergilloma. Jpn J Thorac Cardiovasc Surg. 2000;48:540-541.
10. Jackson D, Greenberg SD, Howell JF. Pulmonary scar carcinoma. A case with two primaries. Cancer. 1984;54:361-366.
11. Yao YT, Wang NS, Michel RP, Poulsen RS. Mineral dusts in lungs with scar or scar cancer. Cancer. 1984;54:1814-1823.
12. Lee BY, Guerra J, Cagir B, Madden RE, Greene JG. Pulmonary scar carcinoma: report of three cases and review of the literature. Mil Med. 1995;160:537-541.
13. Edwards C, Carlile A. Scar adenocarcinoma of the lung: a light and electron microscopic study. J Clin Pathol. 1986;39:423-427.
14. Higashiyama M, Doi O, Kodama K, et al. Immunohistochemical analysis of pancreatic secretory trypsin inhibitor expression in pulmonary adenocarcinoma: its possible participation in scar formation of the tumor tissues. Tumour Biol. 1992;13:299-307.
15. Madri JA, Carter D. Scar cancers of the lung: origin and significance. Hum Pathol. 1984;15:625-631.
16. Kolin A, Koutoulakis T. Role of arterial occlusion in pulmonary scar cancers. Hum Pathol. 1988;19:1161-1167.
17. Auerbach O, Garfinkel L, Parks VR. Scar cancer of the lung: increase over a 21 year period. Cancer 1979;43:636-642.
18. Visscher DW, Yadrandji S, Tabaczka P, Kraut M, Sarkar FH. Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma. Diagn Mol Pathol. 1997;6:64-69.
19. Maeshima AM, Maeshima A, Kawashima O, Nakajima T. K-ras gene point mutation in neogenetic lesions of subpleural fibrotic lesions: either an early genetic event in lung cancer development or a non-specific genetic change during the inflammatory reparative process. Pathol Int. 1999;49:411-418.
20. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996;56:2224-2228.
21. Lee HJ, Im JG, Ahn JM, Yeon KM. Lung cancer in patients with idiopathic pulmonary fibrosis: CT findings. J Comput Assist Tomogr. 1996;20:979-982.
22. Lambe D. Idiopathic interstitial fibrosis. Lung. 1990; 168:S993-S997.
23. Kirishima K, Satoh H, Yamashita YT, Ohtsuka M, Sekizawa K. Unilateral metachronous lung cancers in a patient with idiopathic pulmonary fibrosis. Oncol Rep. 1999;6:763-765.
24. Nakamura Y, Kohzaki S, Suyama N, Yamaguchi T, Kohno S, Hayashi K. Systemic idiopathic fibrosis with inflammatory pulmonary lesions. Br J Radiol. 1997;70:956-958.
25. Vaillant P, Menard O, Vignaud JM, Martinet N, Martinet Y. The role of cytokines in human lung fibrosis. Monaldi Arch Chest Dis. 1996;51:145-152.
26. Martinet Y, Menard O, Vaillant P, Vignaud JM, Martinet N. Cytokines in human lung fibrosis. Arch Toxicol. 1996;18:S127-S139.
27. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol. 1993;143:651-655.
28. Khalil N, O'Connor RN, Flanders KC, Unruh H. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am J Respir Cell Mol Biol. 1996;14:131-138.
29. Iwashita T, Kadota J, Naito S, et al. Involvement of collagen-binding heat shock protein 47 and procollagen type I synthesis in idiopathic pulmonary fibrosis: contribution of type II pneumocytes to fibrosis. Hum Pathol. 2000;31:1498-1505.
30. Wahl SM. Inflammation and growth factors. J Urol. 1997;157:303-305.
31. Uhl EW, Castleman WL, Sorkness RL, Busse WW, Lemanske RF, McAllister PK. Parainfluenza virus-induced persistence of airway inflammation, fibrosis, and dysfunction associated with TGF-beta 1 expression in brown Norway rats. Am J Respir Crit Care Med. 1996;154:1834-1842.
32. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today. 1991;12:17-23.
33. Leirisalo-Repo M. The present knowledge of the inflammatory process and the inflammatory mediators. Pharmacol Toxicol. 1994;75(Suppl. 2):1-3.
34. Baldwin A. The NFκβ and Iκβ proteins: new discoveries and insights. Ann Rev Immunol. 1996;14:649-683.
35. Manning AM, Bell FP, Rosenbloom CL, et al. NF-κβ activated during acute inflammation in vivo in association with elevated endothelial cell adhesion molecule expression and leukocyte recruitment. J Inflammation. 1995;45:283-296.
36. Feng L, Xia Y, Garcia GE, Hwang D, Dawson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest. 1995;95:1669-1675.
37. DeForge LE, Preston AM, Takeuchi E, Kenney J, Boxer LA, Remick DG. Regulation of interleukin 8 gene expression by oxidant stress. J Biol Chem. 1993;268:25568-25576.
38. Zhang D, Jiang SL, Rzewnicki D, Samols D, Kushner I. The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J. 1995;310:143-148.
39. Masamune A, Sakai Y, Kikuta K, Satoh M, Satoh A, Shimosegawa T. Activated rat pancreatic stellate cells express intercellular adhesion molecule-1 (ICAM-1) in vitro. Pancreas. 2002;25:78-85.
40. Khan I, Collins SM. Expression of cytokines in the longitudinal muscle myenteric plexus of the inflamed intestine of the rat. Gasteroenterology. 1994;107:691-700.
41. Rahman A, Anwar KN, Malik AB. Protein kinase C-zeta mediates TNF-alpha-induced ICAM-1 gene transcription in endothelial cells. Am J Physiol Cell Physiol. 2000;279:906-914.
42. Zadeh MS, Kolb JP, Geromin D, et al. Regulation of ICAM-1/CD54 expression on human endothelial cells by hydrogen peroxide involves inducible NO synthase. J Leukoc Biol. 2000;67:327-334.
43. Nagineni CN, Kutty RK, Detrick B, Hooks JJ. Inflammatory cytokines induce intercellular adhesion molecule-1 (ICAM-1) mRNA synthesis and protein secretion by human retinal pigment epithelial cell cultures. Cytokine. 1996;8:622-630.
44. Zor U, Ferber E, Gergely P, Szucs K, Dombradi V, Goldman R. Reactive oxygen species mediate phorbol ester-regulated tyrosine phosphorylation and phospholipase A2 activation: potentiation by vanadate. Biochem J. 1993;295:879-888.
45. Chakraborti S, Gurtner GH, Michael JR. Oxidant-mediated activation of phospholipase A2 in pulmonary endothelium. Am J Physiol. 1989;257:L430-L437.
46. Bonventre JV, Swidler M. Calcium dependency of prostaglandin E2 production in rat glomerular mesangial cells. Evidence that protein kinase C modulates the Ca2+ dependent activation of phospholipase A2. J Clin Invest. 1988;82:168-176.
47. Handlogten ME, Huang C, Shiraishi N, Awata H, Miller RT. The Ca2+ sensing receptor activates cytosolic phospholipase A2 via a Gq alpha-dependent ERK-independent pathway. J Biol Chem. 2001;276:13941-13948.
48. Qiu ZH, Gijon MA, de Carvalho MS, Spencer DM, Leslie CC. The role of calcium and phosphorylation of cytosolic phospholipase A2 in regulating arachidonic acid release in macrophages. J Biol Chem. 1998;273:8203-8211.
49. Kramer RM, Sharp JD. Structure, function and regulation of Ca2+sensitive cytosolic phospholipase A2 (cPLA2). FEBS Lett. 1997;410:49-53.
50. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431-502.
51. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA. 1993;90:7915-7922.
52. Ames BN, Shigenaga MN, Gold LS. DNA lesions, inducible DNA repair, and cell divisions: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect. 1993;101S:35-44.
53. Chung F-L, Xu Y. Increased 8-oxodeoxyguanosine levels in lung DNA of A/J mice and F344 rats treated with the tobacco-specific nitrosamine 4-(methyl-nitrosamino)-1-(pyridyl)-1-butanone. Carcinogenesis. 1992;13:269-1272.
54. Meyers M, Pahl HL, Baeuerle RA. Regulation of the transcription factors NF-κβ and AP-1 by redox changes. Chem-Biol Interact. 1994;91:91-100.
55. Huot J, Lambert H, Lavoie JN, Guimond A, Houle G, Landry J. Characterization of 45-kDa/54-kDa HSP27 kinase, a stress sensitive kinase which may activate the phosphorylation-dependent protective function of mammalian 27-dKa heat shock protein HSP27. E J Biochem. 1995;227:416-427.
56. Larson R, Cerutti P. Translocation and enhancement of phosphotransferase activity of protein kinase C following exposure of mouse epidermal cells to oxidants. Cancer Res. 1089;49:5627-5632.
57. Cerutti P, Shah G, Peskin A, Amstad P. Oxidant carcinogenesis and antioxidant defense. Ann N Y Acad Sci. 1992;663:158-166.
58. Boyle WJ, Smeal T, Defize LHK, et al. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA binding activity. Cell. 1991;64:573-584.
59. Volm M, Drings P, Wodrich W, van Kaick G. Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases. Clin Exp Metastasis. 1993;11:325329.
60. Bergh JC. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes. Am Rev Respir Dis. 1990;142:S20-S26.
61. Szabo E, Riffe ME, Steinberg SM, Birrer MJ, Linnoila RI. Altered cJUN expression: an early event in human lung carcinogenesis. Cancer Res. 1996;56:305-315.
62. Giri RK, Baral RN, Das BR. Induction of lung carcinogenesis in AKR-mice by N-nitrosodiethylamine/phenobarbitone, associated with high expression of c-myc and c-jun oncoproteins. Cancer Lett. 1997;112:57-63.
63. Volm M, van Kaick G, Mattern J. Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases. Clin Exp Metastasis. 1994;12:329-334.
64. Witte CL, Witte MH. Disorders of lymph flow. Acad Radiol. 1995;2:324-334.
65. Franke-Ullmann G, Pfortner C, Walter P, Steinmuller C, Lohmann-Mat ML, Kobzik L. Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro. J Immunol. 1996;157:3097-3104.
66. DesJardin LE, Kaufman TM, Potts B, Kutzbach B, Yi H, Schlesinger LS. Accessory function and costimulatory molecule expression of alveolar macrophages in patients with pulmonary tuberculosis. Immunobiology. 2000;201:450-460.
67. Dannenberg AM Jr. Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Immunobiology. 1994;191:461-473.
68. Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann Rheum Dis. 2002;61(S2):54-58.
69. Riendeau CJ, Kornfeld H. THP-1 cell apoptosis in response to mycobacterial infection. Infect Immunol. 2003;71:254-259.
70. Wang L, Antonini JM, Rojanasakul Y, Castranova V, Scabilloni JF, Mercer RR. Potential role of apoptotic macrophages in pulmonary inflammation and fibrosis. J Cell Physiol. 2003;194:215-224.
71. Jackson BA, Goldstein RH, Roy R, Cozzani M, Taylor L, Polgar P. Effects of transforming growth factor beta and interleukin-1 beta on expression of cyclooxygenase 1 and 2 and phospholipase A2 mRNA in lung fibroblasts and endothelial cells in culture. Biochem Biophys Res Commun. 1993;197:1465-1474.
72. Samet JM, Ghio AJ, Costa DL, Madden MC. Increased expression of cyclooxygenase 2 mediates oil fly ash-induced lung injury. Exp Lung Res. 2000;26:57-69.
73. Timblin C, BeruBe K, Churg A, et al. Ambient particulate matter causes activation of the c-jun kinase/stress-activated protein kinase cascade and DNA synthesis in lung epithelial cells. Cancer Res. 1998;58:4543-4547.
74. Chung YW, Jeong DW, Won JY, Choi EJ, Choi YH, Kim IY. H(2)O(2)-induced AP-1 activation and its effect on p21(WAF1/CIP1)-mediated G2/M arrest in a p53-deficient human lung cancer cell. Biochem Biophys Res Commun. 2002;293:1248-1253.
75. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys. 2003;410:177-185.
76. Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci. 2001;31:325-348.
77. Kase S, Osaki M, Honjo S, et al. Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch. 2003;442(2):129-135.
78. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002;62: 6323-6328.
79. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19:19-27.
80. Sasaki H, Sato T, Yamauchi N, et al. Induction of heat shock protein 47 synthesis by TGF-beta and IL-1 beta via enhancement of the heat shock element binding activity of heat shock transcription factor 1. J Immunol. 2002;168:5178-5183.
81. Haidaris PJ. Induction of fibrinogen biosynthesis and secretion from cultured pulmonary epithelial cells. Blood. 1997;89:873-882.
82. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids. 1996;54:83-94.
83. Schwartz J. Role of polyunsaturated fatty acids in lung disease. Am J Clin Nutr. 2000;71:393S-396S.
84. Suganuma M, Ohkura Y, Okabe S, Fujiki H. Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice. J Cancer Res Clin Oncol. 2001;127:69-72.
85. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H. Synergistic effects of (-)-epigallocatechin gallate with (-)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res. 1999;59:44-47.
86. Wallace JM. Nutritional and botanical modification of the inflammatory cascade-eicosanoids, cyclooxygenases, and lipoxygenases-as an adjunct in cancer therapy. Integrat Cancer Ther. 2002;1:7-37.
87. Ardies CM. Exercise, cachexia, and cancer therapy: a molecular rationale. Nutr Cancer. 2002;42:143-157.